newsday News
Most Popular newsday Story
OSI licenses diabetes drug to Lilly in $385M pact
OSI has licensed the exclusive rights to PSN010--its early-stage diabetes drug--to Eli Lilly for $25 million up front and up to $360 million in milestones plus royalty payments. The drug is designed to fight type 2 diabetes by promoting glucokinase, a protein that prompts the pancreas to make more insulin while promoting better control of glucose.
David Moller, M.D., Lilly's vice president, endocrine and cardiovascular research and clinical investigation commented: "This …
Read more...Latest Headlines
- January 4, 2007
- May 24, 2006
- February 13, 2006
- November 10, 2005
- October 24, 2005
- October 6, 2005
- September 25, 2005
- September 11, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
